LOS ANGELES--(BUSINESS WIRE)--Response Genetics, Inc. (NASDAQ: RGDX), a company focused on the development of molecular diagnostic tests for cancer, today announced its consolidated financial results for the second quarter of 2008, and six months ended June 30, 2008.
